Singapore markets open in 5 hours 50 minutes

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
10.28+0.39 (+3.94%)
As of 03:10PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 1.51B
Enterprise value 1.17B
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.20
Enterprise value/revenue N/A
Enterprise value/EBITDA -3.26

Trading information

Stock price history

Beta (5Y monthly) 0.50
52-week change 3-58.43%
S&P500 52-week change 3-16.34%
52-week high 327.96
52-week low 36.18
50-day moving average 311.50
200-day moving average 313.83

Share statistics

Avg vol (3-month) 32.52M
Avg vol (10-day) 32.3M
Shares outstanding 5157.8M
Implied shares outstanding 6N/A
Float 8128.12M
% held by insiders 10.61%
% held by institutions 1106.86%
Shares short (30 Aug 2022) 419.65M
Short ratio (30 Aug 2022) 48.31
Short % of float (30 Aug 2022) 413.09%
Short % of shares outstanding (30 Aug 2022) 412.45%
Shares short (prior month 28 Jul 2022) 419.42M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:100
Last split date 325 Sept 2013

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-32.21%
Return on equity (ttm)-61.85%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -370.74M
Net income avi to common (ttm)-376.41M
Diluted EPS (ttm)-2.30
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)424.46M
Total cash per share (mrq)2.69
Total debt (mrq)80.48M
Total debt/equity (mrq)17.03
Current ratio (mrq)6.72
Book value per share (mrq)2.99

Cash flow statement

Operating cash flow (ttm)-262.98M
Levered free cash flow (ttm)-162.45M